drugset / Trial / NCT00452790

Study Evaluating 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants in India

NCT00452790

Phase 3 Completed 708 enrolled Wyeth is now a wholly owned subsidiary of Pfizer
RandomizedParallel-groupQuadruple-blindPrevention

Summary

The purpose of this study is to assess the safety, tolerability and immunogenicity of a 13-valent pneumococcal conjugate vaccine (13vPnC) compared to Prevenar (7vPnC), when given concomitantly with routine paediatric vaccinations in India.

Timeline

Start
2007-06
Primary completion
2009-10
Completion
2010-02

Drugs

EvaluationDrugModalityDoseRoute
Comparator Prevnar 13 Vaccine